In Deep Brain Stimulation, Sapiens Adopts Wise Model
This article was originally published in Start Up
Executive Summary
In early June, young company Sapiens Steering Brain Stimulation raised the largest Series A round that a device company in Europe, perhaps even in they US, has enjoyed in five years. Sapiens aims to solve several key challenges hindering deep brain stimulation: divorcing the therapeutic effect of stimulation from the unintended side effects, making the device MRI-compatible and providing physicians with an integrated image-guided procedure.
You may also be interested in...
Medtronic And Covidien Continue Shopping In Advance Of Pairing
Medtronic and Covidien have announced two deals each in the past week. The two firms are set to be combined by early next year under a megadeal announced in June.
Deep Brain Stimulation Probes New Frontiers
Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.
Intelect Medical Inc.
Intelect Medical brings together a patent portfolio from the Cleveland Clinic and Cornell's Weill Medical College, and a management team experienced in neuromodulation, to usher in a new generation of deep brain stimulation. The start-up's initial target markets are traumatic brain injury and stroke.